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Bordetella holmesii is a recently described
gram-negative, asaccharolytic, nonoxidizing,
soluble, brown-pigment-producing rod previ-
ously known as CDC nonoxidizer group 2 (NO-2)
(1). This group consists of 15 closely related,
biochemically similar strains of fastidious
nonmotile bacteria isolated from human blood
cultures. In establishing NO-2 as a species,
Weyant et al. (1) performed 16S rRNA
sequencing of one NO-2 strain and the type
strains of B. pertussis, B. parapertussis,
B. bronchiseptica, and B. avium. They found a
high degree of homology among them (³98%
over 1,525 bases) and confirmed a close
relatedness between NO-2 and Bordetella
species by DNA relatedness studies (hydroxya-
patite method). Biochemically, the lack of
oxidase activity and the production of a brown
soluble pigment differentiate B. holmesii from
B. pertussis, B. bronchiseptica, and B. avium;
the lack of urease activity differentiates it
from  B. parapertussis (1).
Unlike B. pertussis, which causes whooping
cough,  B. holmesii has been associated most
often with septicemia in patients with underly-
ing conditions (1-4). It also has been isolated from
sputum from one patient with respiratory
symptoms (3). Van den Akker (5) suggested that
the difference in lipopolysaccharide expression
(important in bacterial pathogenesis) between
the closely related B. pertussis and B. holmesii
might help explain their observed difference in
propensity to infect respiratory tract epithelium
verses causing opportunistic bacteremia.
In Massachusetts, however, we have seen
B. holmesii associated with a different clinical
picture. From January 1995 (when the article
describing  B. holmesii [1] was published)
through December 1998, the Massachusetts
State Laboratory Institute (SLI) isolated
B. holmesii from 34 clinical specimens: 33
nasopharyngeal specimens from patients sus-
pected of having pertussis and one blood culture
specimen from a 45-year-old patient with
septicemia. Of the 33 patients with respiratory
symptoms, 30 (91%) were 11 to 29 years old, 1
(3%) was an infant, and 2 (6%) were 10 years old;
most were otherwise healthy.
B. holmesii is confirmed by its biochemical
patterns and cellular fatty acid analysis or the
DNA transformation test will definitively
separate  B. holmesii from Acinetobacter, neither
procedure is performed at SLI. Three of the
initial isolates were sent to the Centers for
Disease Control and Prevention, Atlanta, Georgia,
for definitive identification and were confirmed
as B. holmesii by cellular fatty acid analysis. The
remaining 31 isolates were biochemically and
morphologically identical to those.
B. holmesiipositive nasopharyngeal speci-
mens have increased both in absolute number
and as a percentage of the total nasopharyngeal
specimens processed at SLI (Table). The number
rose from 3 (0.1% of total specimens submitted
for pertussis culture) in 1995, to 6 (0.2%) in 1996,
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Table. Bordetella species isolated from nasopharyngeal (NP) specimens at the Massachusetts State Laboratory
Institute, 1994–1998
1994 1995 1996 1997 1998
No.  % No.  % No.  % No.  % No.  %
B. pertussis      75 4.2   140 5.8    325 8.9   132 5.6    165 6.6
B. parapertussis        7 0.4     20 0.8      32 0.9     11 0.5   NA NA
B. holmesii        0 0       3a 0.1        6 0.2       9 0.4      15 0.6
Total NP specimens 1,792 2,399 3,653 2,375 2,508
  reported
aDoes not include the one case of B. holmesii isolated from blood.
to 9 (0.4%) in 1997, and to 15 (0.6%) in 1998. A
chi-square analysis for linear trend of propor-
tions from 1995 to 1998 found the trend
significant (chi-square = 11.6, p <.001), possibly
indicating a rise in prevalence. (When such an
analysis was applied to the proportion of
nasopharyngeal specimens testing positive for
pertussis during the same period, no trend was
apparent ([chi-square = 0.8, p = .36].) A growing
awareness of the species by laboratory personnel
may be contributing to the observed increase.
To ascertain what symptoms were associated
with B. holmesii isolation, we investigated the 23
cases identified in the 24 months from January
1997 through December 1998. We called
providers and patients for disease histories and
demographic information. Pertussis case report
forms, modified to include more possible
symptoms and underlying conditions, were used
to record the information collected in the
interviews.
Nineteen (83%) of the 23 B. holmesii-positive
cases were in adolescents (11 to 19 years), 2 (9%)
in young adults (20 and 29 years), 1 (4%) in a 10-
year-old child, and 1 (4%) in an infant. All had
cough. In addition, 14 (61%) had paroxysms,
2 (9%) had whoop, and 6 (26%) had posttussive
vomiting. No other symptoms were identified by
patients or providers. Fourteen (61%) of the 23
had no underlying conditions, 8 (35%) had minor
conditions such as occasional asthma or
allergies, and 1 (4%) had chronic fatigue.
The fact that cultures were taken from 20
(87%) of the 23 case-patients within 14 days of
cough onset generally excluded convalescent-
stage pertussis as a cause of symptoms.
However,  B. pertussis had been confirmed in a
14-year-old girl, who had occasional asthma,
3 months before B. holmesii was confirmedshe
received a reculture because of a persistent
cough that had not resolved since the original
infection. She had had paroxysms and vomiting
associated with the pertussis infection but no
symptoms other than cough at the time
B. holmesii was isolated. Cultures were taken on
the same day from two sisters, 15 and 9 years old,
each with cough of fewer than 14 days.
B. holmesii was culture-confirmed in the 15-
year-old; B. pertussis was culture-confirmed in
the 9-year-old. This raises the question of
whether B. pertussis and B. holmesii might
cocirculate.
At least 11 (48%) of the 23 cases were found
during active surveillance for pertussis in school
and university settings, which may explain the
age profile of the cases. Three case-patients, with
cough onset dates of April 1, 1997; February 27,
1998; and March 9, 1998, were students at the
same university. These cases, though not
epidemiologically linked to each other, were in
symptomatic contacts of pertussis patients and
were cultured as part of an azithromycin efficacy
study. At least eight other cases were also in
contacts of confirmed patients with pertussis and
were detected through active surveillance. No
cases were definitively linked. Peak months of
cough onset were November and December (8 of
the 23 cases), as is true for pertussis in
Massachusetts, with a smaller peak in March
and April (6 of the 23 cases). The observed peak
in November-December may be due to the role of
active surveillance for pertussis in ascertaining
cases of B. holmesii colonization.
The clinical profile of the 21 cases in
adolescent and adult patients infected with
B. holmesii was compared with that of 122
culture-confirmed pertussis cases in patients
between 11 and 29 years of age with cough onsets
in the same period, i.e., 1997 through 1998.
(Relevant clinical information was not available
for an additional 42 culture-confirmed pertussis
case-patients in this age group.) We did not
consider cough duration, because of imprecise
data, but rather focused on the presence or
absence of three classic pertussis symptoms:
paroxysms of cough, whoop, and posttussive443 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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vomiting. Cases were categorized as patients
with 0, 1, or 2 to 3 of these symptoms. (No
separate category for three symptoms was used
due to a cell size of 0 in the case of B. holmesii.)
On applying the chi-square test for independent
proportions, we found B. holmesii infection
milder (i.e., accompanied by fewer of the above
three pertussis symptoms) than B. pertussis
infection (chi-square = 10, p <.01).
To rule out the possibility that the difference
was due to more frequent cultures for severe
than for milder pertussis cases, we compared the
21 adolescent and adult B. holmesii patients with
the 577 SLIserology-positive pertussis patients
11 to 29 years of age with cough onsets in 1997 or
1998 for whom sufficient clinical data were
available. The SLI pertussis serology test is a
single-serum enzyme-linked immunosorbent
assay for immunoglobulin G to pertussis toxin,
available since 1987. The assay is for use in
persons ³ 11 years of age and is optimally
sensitive at 2 to 8 weeks after cough onset. By
the same methods as for the previous
comparison, we found that the B. holmesii
cases were milder at a higher level of
significance (chi-square = 69, p <10-8).
Without knowing the prevalence of
B. holmesii carriage in asymptomatic persons,
we cannot say with certainty that B. holmesii is
the causative agent for the respiratory
symptoms of the patients from whom it was
isolated. Approximately half the cases were
discovered through active surveillance for
pertussis. This, together with the fact that the
symptoms associated with B. holmesii were
relatively mild, suggests that the organism may
not have been causing disease. On the other
hand, B. holmesii may be the etiologic agent,
given that it is closely related to B. pertussis and
the associated symptoms (like those of
B. parapertussis) are similar. B. pertussis is the
only  Bordetella species known to produce
pertussis toxin, although B. parapertussis and
B. bronchiseptica have silent copies of the toxin
gene (6). We do not know whether B. holmesii
has the toxin gene. However, since
B. parapertussis can cause disease (albeit not as
severe as B. pertussis [7]), the presence of
pertussis toxin is not necessary for the
development of symptoms.
Continued investigation, including conduct-
ing diagnostic tests for agents such as
Chlamydia and Mycoplasma and culturing
symptomatic and asymptomatic contacts, is
warranted to ascertain the degree to which
B. holmesii is pathogenic in the respiratory
system and contagious. If it is contagious,
antibiotic susceptibility testing is also
needed.  B. holmesii is susceptible to some 15
antibiotics of a variety of classes (2,3), but
whether erythromycin, the drug of choice for
pertussis, is effective is not known. SLI is
establishing routine erythromycin susceptibility
testing of B. pertussis and will also test B. holmesii
isolates.
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